Tag: acquisition

New York, N.Y., July 03, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it is the Platinum Sponsor of the upcoming Defense Strategies Institute’s 7^th Annual DoD Energy & Power Summit to be held on July 9-10, 2025, at the National Housing Center in Washington, DC.

MIAMI, July 03, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, today announces that it has received a Notification of Disposition of Collateral (the "Notice") from Anthony J. DePaul, as Agent and Secured Party under the Pledge Agreement dated as of October 1, 2021 between CSAC Acquisition PA II Corp., a subsidiary of the Company, and the Agent (the "Pledge Agreement"). Separately, the Company announces that it has entered into an additional amendment (the “Second Amendment”) to the previously disclosed Limited Waiver Agreement dated June 6, 2025 (the “Original Agreement”), as amended on June 19, 2025 (the “First Amendment”).

FORM 8.5 (EPT/RI)

Q3 Fiscal 2025 Revenues

VANCOUVER, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. ("CLC" or the "Company") (CSE: CLC) announced today that it will not be filing its annual financial statements, accompanying management's discussion and analysis and related chief executive officer ("CEO") and chief financial officer ("CFO") certifications for the financial year ended February 28, 2025 (collectively, the "Annual Filings"), within the period prescribed for the filing of such documents under Parts 4, 5 and 6 of National Instrument 51-102 Continuous Disclosure Obligations and pursuant to National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, namely within 120 days of year-end, being June 30, 2025 (the "Filing Deadline").

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

MONTRÉAL, 02 juill. 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’hui qu’elle a conclu une convention d’arrangement contraignante avec CB Biotechnology, LLC (l’« Acquéreur »), un membre du même groupe que Future Pak, LLC (« Future Pak »), une société fermée de fabrication, de conditionnement et de distribution à façon de produits pharmaceutiques et nutraceutiques. Aux termes de la convention d’arrangement, l’Acquéreur acquerra toutes les actions ordinaires émises et en circulation de la Société pour 3,01 $ US par action en espèces, plus un droit conditionnel à la valeur (« DCV ») par action représentant des paiements supplémentaires totaux en espèces pouvant atteindre 1,19 $ US par DCV si certains jalons décrits plus en détail ci-après sont atteints (l’« Opération »). La contrepartie totale de l’Opération, en supposant le paiement intégral des DCV, se chiffre à 254 millions de dollars américains.